| 1 | 10146 | LAO-CT018 | ETCTN | Breast Cancer | Active | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer | II | 66/70 | N/A | INTERVENTION |
| 2 | 10237 | LAO-11030 | ETCTN | Leukemia | Temporarily Closed to Accrual | A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes with Increased Blasts | I | 12/42 | 13 | SCREENING, INTERVENTION |
| 3 | 10292 | LAO-NCI | ETCTN | Solid Tumor | Active | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors | II | 82/115 | N/A | INTERVENTION |
| 4 | 10299 | LAO-NCI | ETCTN | Lymphoma;Solid Tumor | Active | A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients | I | 4/95 | N/A | INTERVENTION |
| 5 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 18/27 | N/A | INTERVENTION |
| 6 | 10505 | LAO-CA043 | ETCTN | CNS Cancer (Primary tumor) | Active | A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma | I/II | 51/84 | N/A | INTERVENTION |
| 7 | 10528 | LAO-MA036 | ETCTN | Solid Tumor | Active | A Phase 1 Study of the Polymerase Theta (POL¿) Inhibitor Novobiocin in BRCA- Mutant and Other DNA Damage Repair-Deficient Solid Tumors | I | 18/43 | N/A | INTERVENTION |
| 8 | 10579 | LAO-PA015 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Active | Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors | I | 23/30 | N/A | INTERVENTION |
| 9 | 10629 | LAO-MD017 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer | I/II | 13/24 | N/A | INTERVENTION |
| 10 | 10630 | LAO-PA015 | ETCTN | Leukemia | Temporarily Closed to Accrual | Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine in Patients with Treatment Naive AML | I | 8/45 | N/A | INTERVENTION |
| 11 | 10695 | LAO-MA036 | ETCTN | Leukemia | Temporarily Closed to Accrual &Treatment | Phase 1 Study of Lintuzumab-Ac225 Monotherapy for Patients with Hypomethylating Agent-Refractory Myelodysplastic Syndrome | I | 0/18 | N/A | INTERVENTION |
| 12 | A032102 | ALLIANCE | NCTN | Male Reproductive System Cancer | Active | PREcision DIagnostics in Prostate Cancer Treatment (PREDICT) | II | 35/474 | N/A | INTERVENTION |
| 13 | A032304 | ALLIANCE | NCTN | Male Reproductive System Cancer | Active | Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL) | III | 10/1524 | N/A | INTERVENTION |
| 14 | A041501 | ALLIANCE | NCTN | Leukemia | Active | A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL | III | 291/303 | N/A | INTERVENTION |
| 15 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 65/84 | N/A | INTERVENTION |
| 16 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 121/182 | N/A | INTERVENTION |
| 17 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 97/124 | 532 | SCREENING, INTERVENTION |
| 18 | A072201 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Temporarily Closed to Accrual | Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma | II | 117/184 | N/A | INTERVENTION |
| 19 | A082101 | ALLIANCE | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | Multimodality Therapy with Immunotherapy in Stage I-IIIA Pleural Mesothelioma | II | 10/26 | N/A | INTERVENTION |
| 20 | ARAR2221 | COG | NCTN | Head and Neck Cancer | Active | A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) | II | 39/50 | N/A | INTERVENTION |
| 21 | CCTG-NE1 | CCTG | NCTN | Endocrine Cancer | Active | NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours | II | 44/100 | N/A | INTERVENTION |
| 22 | CCTG-PR26 | CCTG | NCTN | Male Reproductive System Cancer | Active | A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) | III | 24/830 | N/A | INTERVENTION |
| 23 | EA1242 | ECOG-ACRIN | NCTN | Breast Cancer | Active | A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS | III | 0/1978 | 0 | SCREENING, INTERVENTION |
| 24 | EA2174 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma | II/III | 275/278 | N/A | INTERVENTION |
| 25 | EA2185 | ECOG-ACRIN | NCORP | Gastrointestinal Cancer | Active | Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | II | 558/750 | N/A | INTERVENTION |
| 26 | EA2192 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | II | 113/152 | N/A | INTERVENTION |
| 27 | EA4232 | ECOG-ACRIN | NCTN | Lymphoma | Active | A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) | III | 11/294 | N/A | INTERVENTION |
| 28 | EA8192 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | II/III | 105/129 | N/A | INTERVENTION |
| 29 | EA9213 | ECOG-ACRIN | NCTN | Leukemia | Active | A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) | II | 18/20 | N/A | INTERVENTION |
| 30 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 259/288 | N/A | INTERVENTION |
| 31 | EAY191 | ECOG-ACRIN | NCTN | Lymphoma;Solid Tumor | Active | Molecular Analysis for Combination Therapy Choice (ComboMATCH) | Other | N/A | 618 | SCREENING |
| 32 | EAY191-N5 | NRG | NCTN | Bone Cancer;CNS Cancer (Primary tumor);Endocrine Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Germ Cell Cancer;Head and Neck Cancer;Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Miscellaneous and Metastatic Cancer;Skin Cancer;Soft Tissue Cancer/Sarcoma;Solid Tumor;Urothelial/ Bladder Cancer | Active | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial | II | 41/70 | N/A | INTERVENTION |
| 33 | NRG-CC013 | NRG | NCORP | Head and Neck Cancer | Active | A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation | II | 69/98 | N/A | INTERVENTION |
| 34 | NRG-CC015 | NRG | NCORP | Breast Cancer | Active | Harnessing E-Mindfulness Approaches for Living After Breast Cancer --- HEAL-ABC | III | 164/402 | N/A | INTERVENTION |
| 35 | NRG-GU012 | NRG | NCTN | Kidney Cancer | Active | Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) | II | 145/240 | N/A | INTERVENTION |
| 36 | NRG-GY032 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER) | II | 63/395 | N/A | INTERVENTION |
| 37 | NRG-GY037 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer | III | 58/336 | N/A | INTERVENTION |
| 38 | PEPN2111 | PEP-CTN | MISCELLANEOUS | Bone Cancer;CNS Cancer (Primary tumor);Lymphoma;Solid Tumor | Temporarily Closed to Accrual | A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients with Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma | I/II | 27/38 | N/A | INTERVENTION |
| 39 | S1703 | SWOG | NCORP | Breast Cancer | Active | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer | Other | 461/498 | 694 | SCREENING, INTERVENTION |
| 40 | S1800E | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) | II/III | 110/378 | N/A | INTERVENTION |
| 41 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 163/189 | N/A | INTERVENTION |
| 42 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
| 43 | S2209 | SWOG | NCTN | Myeloma | Active | A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance | III | 136/510 | N/A | INTERVENTION |
| 44 | S2409 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) | II | 8/292 | 41 | SCREENING, INTERVENTION |
| 45 | SN2426 | SWOG | NCTN | Skin Cancer | Temporarily Closed to Accrual | A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma | II | 7/86 | N/A | INTERVENTION |
| 46 | WF-1901 | WAKE | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) | III | 246/250 | N/A | INTERVENTION |
| 47 | 10487 | LAO-MD017 | ETCTN | Male Reproductive System Cancer | Active | A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation | II | 27/25 | N/A | INTERVENTION |
| 48 | 10492 | LAO-11030 | ETCTN | Head and Neck Cancer | Active | Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer | I | 24/46 | N/A | INTERVENTION |
| 49 | 10554 | LAO-TX035 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Active | Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors | I | 10/48 | N/A | INTERVENTION |
| 50 | 10559 | LAO-11030 | ETCTN | CNS Cancer (Primary tumor) | Active | A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion | II | 30/30 | N/A | INTERVENTION |